A post-marketing clinical study to evaluate the efficacy and safety of pertuzumab combined with trastuzumab and docetaxel as first line treatment in HER2- positive inoperable or recurrent breast cancer

Trial Profile

A post-marketing clinical study to evaluate the efficacy and safety of pertuzumab combined with trastuzumab and docetaxel as first line treatment in HER2- positive inoperable or recurrent breast cancer

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Pertuzumab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms COMACHI
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 10 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top